About this Journal Submit a Manuscript Table of Contents
Case Reports in Medicine
Volume 2012 (2012), Article ID 657694, 4 pages
http://dx.doi.org/10.1155/2012/657694
Case Report

Refractory Gout Attack

Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo (USP), Avenida Doutor Arnaldo 455, 01246-903 São Paulo, SP, Brazil

Received 11 August 2012; Revised 26 October 2012; Accepted 29 October 2012

Academic Editor: J. W. M. Van der Meer

Copyright © 2012 Simone Fargetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. K. Reinders and T. L. Jansen, “New advances in the treatment of gout: review of pegloticase,” Therapeutics and Clinical Risk Management, vol. 6, pp. 543–550, 2010. View at Publisher · View at Google Scholar
  2. E. Fels and J. S. Sundy, “Refractory gout: what is it and what to do about it?” Current Opinion in Rheumatology, vol. 20, no. 2, pp. 198–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Becker-Capeller, K. Melker, and M. H. Weber, “The polyarticular gout—change of the clinical picture?” Zeitschrift fur Arztliche Fortbildung, vol. 90, no. 3, pp. 227–231, 1996. View at Scopus
  4. C. O. Garcia, A. G. Kutzbach, and L. R. Espinoza, “Characteristics of gouty arthritis in the Guatemalan population,” Clinical Rheumatology, vol. 16, no. 1, pp. 45–50, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. G. V. Lawry II, P. T. Fan, and R. Bluestone, “Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features,” Medicine, vol. 67, no. 5, pp. 335–343, 1988. View at Scopus
  6. O. L. Meyers and F. S. E. Monteagudo, “Gout in females: an analysis of 92 patients,” Clinical and Experimental Rheumatology, vol. 3, no. 2, pp. 105–109, 1985. View at Scopus
  7. D. J. McCarty, “Gout without hyperuricemia,” The Journal of the American Medical Association, vol. 271, no. 4, pp. 302–303, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. N. M. Hadler, W. A. Franck, N. M. Bress, and D. R. Robinson, “Acute polyarticular gout,” American Journal of Medicine, vol. 56, no. 5, pp. 715–719, 1974. View at Scopus
  9. A. P. Hall, P. E. Barry, T. R. Dawber, and P. M. McNamara, “Epidemiology of gout and hyperuricemia. A long-term population study,” The American Journal of Medicine, vol. 42, no. 1, pp. 27–37, 1967. View at Scopus
  10. N. Dalbeth and D. O. Haskard, “Mechanisms of inflammation in gout,” Rheumatology, vol. 44, no. 9, pp. 1090–1096, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Martin and J. L. Harper, “Innate inflammation and resolution in acute gout,” Immunology and Cell Biology, vol. 88, no. 1, pp. 15–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Pascual, E. Batlle-Gualda, A. Martínez, J. Rosas, and P. Vela, “Synovial fluid analysis for diagnosis of intercritical gout,” Annals of Internal Medicine, vol. 131, no. 10, pp. 756–759, 1999. View at Scopus
  14. M. K. Reinders, C. Haagsma, T. L. T. A. Jansen et al., “A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100–200 mg/day in patients with gout,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 892–897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. H. H. Lee, G. G. Graham, K. M. Williams, and R. O. Day, “A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?” Drug Safety, vol. 31, no. 8, pp. 643–665, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Reinders, E. N. van Roon, T. L. T. A. Jansen et al., “Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 51–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. K. Tausche, K. Richter, A. Grässler, S. Hänsel, B. Roch, and H. E. Schröder, “Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor α as a new therapeutic option,” Annals of the Rheumatic Diseases, vol. 63, no. 10, pp. 1351–1352, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Fiehn and M. Zeier, “Successful treatment of chronic tophaceous gout with infliximab (Remicade),” Rheumatology International, vol. 26, no. 3, pp. 274–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. So, T. de Smedt, S. Revaz, and J. Tschopp, “A pilot study of IL-1 inhibition by anakinra in acute gout,” Arthritis Research and Therapy, vol. 9, article R28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Terkeltaub, J. S. Sundy, H. R. Schumacher et al., “The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1613–1617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. So, M. de Meulemeester, A. Pikhlak et al., “Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study,” Arthritis and Rheumatism, vol. 62, no. 10, pp. 3064–3076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Walter-Sack, U. Gresser, M. Adjan et al., “Variation of benzbromarone elimination in man—a population study,” European Journal of Clinical Pharmacology, vol. 39, no. 2, pp. 173–176, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Walter-Sack, J. X. de Vries, A. Ittensohn, and E. Weber, “Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles,” European Journal of Clinical Pharmacology, vol. 39, no. 6, pp. 577–581, 1990. View at Publisher · View at Google Scholar · View at Scopus